Latest news
Parkinson’s Is Trying to Vaccinate Against Progression
A Phase II alpha-synuclein vaccine generated antibodies in every treated participant and reached the cerebrospinal fluid. The immune response is real. Whether it changes Parkinson’s disease is still unanswered.
AI Multiomics Moves Into the Trial Stratification Layer
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
ASCO 2026: Are we overtreating cancer?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.